Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IFB01
- Development stage
- Preclinical
- Lead developer
- Interface Biosciences
- Modality
- Modified Peptides → Peptides
01
Overview
IFB01 is a preclinical-stage sactipeptide therapeutic being developed by Interface Biosciences. Sactipeptides (sulfur-to-alpha-carbon thioether-containing peptides) are a class of ribosomally synthesized and post-translationally modified peptides (RiPPs), often derived from the human microbiome, that possess unique structural stability and biological activity. IFB01 is specifically designed to target and activate the innate immune system. It is currently undergoing optimization for the treatment of innate immune deficiency disorders, inflammatory conditions, and various types of cancer (oncology). The drug represents a novel approach in microbiome-derived peptide therapeutics aimed at modulating host immune responses.
Beyond the preview
Go deeper on IFB01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IFB01.